Elizabeth D Kantor1, Loren Lipworth2, Jay H Fowke2, Edward L Giovannucci1,3, Lorelei A Mucci1,4, Lisa B Signorello1,4. 1. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 2. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 3. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 4. Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.
Abstract
BACKGROUND: Epidemiologic studies suggest that statin use may be inversely associated with risk of prostate cancer, but prior studies have focused predominantly on non-Hispanic white populations. METHODS: We evaluated the association between statin use and prostate cancer risk in the Southern Community Cohort Study (SCCS). Study participants were 32,091 men aged 40-79 at baseline, 67% of whom were non-Hispanic black. Between study enrollment (2002-2009) and December 31, 2010, 570 prostate cancer cases were diagnosed, including 324 low-grade cancers (Gleason score <7 or Gleason pattern 3 + 4) and 107 high-grade cancers (Gleason score >7 or Gleason pattern 4 + 3). Analyses of overall prostate cancer were conducted using Cox regression and analyses of grade-specific cancer were conducted using competing risks models. RESULTS: Ten percent of non-Hispanic black men and 22% of non-Hispanic white men reported use of statins at study enrollment. As compared to non-use, statin use was associated with a non-significant 14% lower risk of prostate cancer in multivariable models (Hazard Ratio [HR]:0.86; 95% Confidence Interval [CI]: 0.63-1.18). This association was stronger for high-grade cancer (HR: 0.62; 95%CI: 0.30, 1.28) than low-grade cancer (HR:0.98; 95%CI: 0.65-1.48). Results were similar by race/ethnicity (p-interaction: 0.41) and did not vary by history of prostate-specific antigen [PSA] screening (p-interaction: 0.65). CONCLUSIONS: Results suggest no strong association between statin use and prostate cancer risk overall, and further suggest that if a modest protective effect does exist, it does not vary by race/ethnicity and may be restricted to high-grade tumors, although power to detect differences by subgroup was limited.
BACKGROUND: Epidemiologic studies suggest that statin use may be inversely associated with risk of prostate cancer, but prior studies have focused predominantly on non-Hispanic white populations. METHODS: We evaluated the association between statin use and prostate cancer risk in the Southern Community Cohort Study (SCCS). Study participants were 32,091 men aged 40-79 at baseline, 67% of whom were non-Hispanic black. Between study enrollment (2002-2009) and December 31, 2010, 570 prostate cancer cases were diagnosed, including 324 low-grade cancers (Gleason score <7 or Gleason pattern 3 + 4) and 107 high-grade cancers (Gleason score >7 or Gleason pattern 4 + 3). Analyses of overall prostate cancer were conducted using Cox regression and analyses of grade-specific cancer were conducted using competing risks models. RESULTS: Ten percent of non-Hispanic black men and 22% of non-Hispanic white men reported use of statins at study enrollment. As compared to non-use, statin use was associated with a non-significant 14% lower risk of prostate cancer in multivariable models (Hazard Ratio [HR]:0.86; 95% Confidence Interval [CI]: 0.63-1.18). This association was stronger for high-grade cancer (HR: 0.62; 95%CI: 0.30, 1.28) than low-grade cancer (HR:0.98; 95%CI: 0.65-1.48). Results were similar by race/ethnicity (p-interaction: 0.41) and did not vary by history of prostate-specific antigen [PSA] screening (p-interaction: 0.65). CONCLUSIONS: Results suggest no strong association between statin use and prostate cancer risk overall, and further suggest that if a modest protective effect does exist, it does not vary by race/ethnicity and may be restricted to high-grade tumors, although power to detect differences by subgroup was limited.
Authors: M R Spitz; S S Strom; Y Yamamura; P Troncoso; R J Babaian; P T Scardino; T Wheeler; C I Amos; A von Eschenbach; J Kagan Journal: Int J Cancer Date: 2000-05-20 Impact factor: 7.396
Authors: Julie K Plenge; Teri L Hernandez; Kathleen M Weil; Paul Poirier; Gary K Grunwald; Santica M Marcovina; Robert H Eckel Journal: Circulation Date: 2002-09-17 Impact factor: 29.690
Authors: Alison M Mondul; Elizabeth Selvin; Angelo M De Marzo; Stephen J Freedland; Elizabeth A Platz Journal: Cancer Causes Control Date: 2010-01-14 Impact factor: 2.506
Authors: Maria I Van Rompay; Keith R Solomon; J Curtis Nickel; Gayatri Ranganathan; Philip W Kantoff; John B McKinlay Journal: Eur J Cancer Date: 2019-03-06 Impact factor: 9.162
Authors: Mahmoud A Alfaqih; Emma H Allott; Robert J Hamilton; Michael R Freeman; Stephen J Freedland Journal: Nat Rev Urol Date: 2016-10-25 Impact factor: 14.432
Authors: Alison M Mondul; Corinne E Joshu; John R Barber; Anna E Prizment; Nrupen A Bhavsar; Elizabeth Selvin; Aaron R Folsom; Elizabeth A Platz Journal: Cancer Prev Res (Phila) Date: 2018-10-16
Authors: Fei Chen; Peggy Wan; Lynne R Wilkens; Loïc Le Marchand; Christopher A Haiman Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-05-04 Impact factor: 4.254
Authors: Christopher J Sweeney; Stephen P Finn; Lorelei A Mucci; Emma H Allott; Ericka M Ebot; Konrad H Stopsack; Amparo G Gonzalez-Feliciano; Sarah C Markt; Kathryn M Wilson; Thomas U Ahearn; Travis A Gerke; Mary K Downer; Jennifer R Rider; Stephen J Freedland; Tamara L Lotan; Philip W Kantoff; Elizabeth A Platz; Massimo Loda; Meir J Stampfer; Edward Giovannucci Journal: Clin Cancer Res Date: 2019-11-21 Impact factor: 12.531
Authors: Jorge Luis Arroyo-Acevedo; Juan Pedro Rojas-Armas; Oscar Herrera-Calderón; Roberto Chávez-Asmat; Hugo Jesús Justil-Guerrero; Cristian Aguilar-Carranza; Edwin Enciso-Roca; Johnny Aldo Tinco-Jayo; Ricardo Ángel Yuli-Posadas; Cesar Franco-Quino; Victor Chumpitaz-Cerrate Journal: Onco Targets Ther Date: 2019-08-15 Impact factor: 4.147